Highlights

Artrya signs five-year commercial SaaS agreement with Tanner Health, valued at US$0.6 million.

First U.S. revenue expected from Salix® Coronary Anatomy platform in current quarter.

Future revenue opportunities from additional modules post-FDA clearance.

Artrya Limited (ASX:AYA), an Australian medical technology company focused on coronary artery disease detection, has announced its first revenue from the U.S. market after securing a five-year agreement with Tanner Health. The deal marks a key milestone for Artrya’s commercial rollout of its Salix® Coronary Anatomy platform and is valued at US$0.6 million.

The Salix® Coronary Anatomy platform, which received U.S. FDA 510(k) clearance in March 2025, will be rolled out across Tanner Health’s network. The commercial Software-as-a-Service (SaaS) agreement includes a monthly subscription fee and potential future fee-per-scan revenues as new modules such as Salix® Coronary Plaque and Salix® Coronary Flow receive FDA clearance.

Tanner Health operates five hospitals and 30 cardiology practices across western Georgia and eastern Alabama. The integration of Artrya’s platform into Tanner’s Picture Archiving and Communications System (PACS) and Electronic Medical Record (EMR) systems enables clinical use on patients with known or suspected coronary artery disease.

Artrya’s Co-Founder and CEO, John Konstantopoulos, noted that the agreement represents the company’s first commercial revenue in the U.S. and provides a framework for further rollouts. "Tanner Health’s adoption of the Salix® platform demonstrates growing trust in our solution and establishes a pathway for future partnerships across U.S. healthcare networks," he said.

Tanner Health’s CEO, Loy Howard, expressed confidence in the Salix® platform, stating that its AI-driven, real-time imaging capabilities offer an important tool for early detection of heart disease. He acknowledged the collaborative effort between Tanner’s clinical and IT teams and Artrya’s integration team throughout the validation and implementation phase.

The commercial agreement is structured with the following terms:

A non-exclusive five-year SaaS licence for use of the Salix® Coronary Anatomy platform.
Monthly subscription fees payable over the contract term.
Future availability of additional modules pending FDA clearance.
Fee-per-scan revenues for additional modules, eligible for reimbursement under Category 1 CPT codes.
Standard termination terms with 30 days’ notice and no cancellation penalties.
Compliance with industry-standard security, privacy, and support protocols.

The agreement positions Artrya for continued expansion in the U.S. as it progresses discussions with other hospital networks including Northeast Georgia Health System and Cone Health. The company is also preparing for FDA submission and commercial launch of the Salix® Coronary Plaque module, which will broaden its product suite and revenue potential.

Artrya’s share price rose by 8.2% to AUD 0.99 on 10 July 2025 following the announcement.